Serology Shortlist for EUA SARS-COV-2 Testing
By mid-September 2020, the list of methods for SARS-COV-2 testing (molecular, antigen, rapid, and serology), broke the 800 mark. Rather than ask laboratories to evaluate more than 800 possibilities, we've narrowed the candidates down to a short list.
Updated September 14, 2020
As of September, only 46 antibody tests have have EUA status from FDA in the US.
Our COVID-19 special coverage:
- This is not a Test https://www.westgard.com/covid19-this-is-not-a-test.htm
- Sprinting into a marathon: https://www.westgard.com/covid-19-marathon.htm
- Key Facts in COVID-19: https://www.westgard.com/covid-19-test-test-test.htm
- Maintaining Quality in a Crisis: https://www.westgard.com/covid-19-maintaining-quality.htm
- Clinical Agreement for Qualitative Testing: https://www.westgard.com/qualitative-test-clinical-agreement.htm
- Clinical Agreement Calculator: http://tools.westgard.com/two-by-two-contingency.shtml
- Prevalence and Predictive Value: https://www.westgard.com/predictive-value.htm
- Predictive Value calculator: http://tools.westgard.com/predictive.shtml
One of the easiest ways to winnow the field is to focus on which manufacturers have submitted and obtained an EUA (Emergency Use Authorization).
Next, is to narrow that further by focusing on methods that have achieved the FDA goal of 90% sensitivity and 95% specificity.
To further flesh out the list, we've been scouring the pre-print services to locate relevant papers that document the real-world performance of these methods. As we know from all other areas of testing, the first set of data on performance, delivered by the manufacturer itself, can sometimes be overly optimistic. What looks great at launch may not be that good in the field. So we can supplement the data from the manufacturer with reality checks from the front lines of the pandemic fight.
There are further sources of data - for instance, the NHS in the UK has evaluations performed by Public Health England Porton Down (PHE Porton Down). The FDA is conducting independent evaluations of serology methods and is releasing those on the Open FDA website. It's also useful to know which methods have been approved in other countries than the US. France, the UK, Canada have publicly accessible lists of their approved methods.
We've noted the sensitivity and specificity of these tests for a specific window of infection, for patients who are >10 or >14 or >15 days from either positive PCR test or symptoms. Given the immunology response curves, it's fruitless to expect IgG or IgM to have a higher sensitivity in the immediate days after infection. This points to the continuing need for PCR testing - in order to detect the active disease, you need the diagnostic test. Serology is for surveillance and history and possible, we hope, proof of immunity.
We have noted, where possible, the number of positive and negative samples used to determine sensitivity and specificity of the methods. More is better. To see a method where they tested thousands of patient samples to determine specificity is heartening. You can have more confidence in that method than one where they tests only 30, 40, 50 samples.
Also note that even if a method doesn't meet the FDA goals for performance, that doesn't automatically discount them for use in your laboratory - particularly if you can consider an orthogonal approach. If you can combine too less-than-perfect tests in confirmatory protocols, you can get a better combined result than either single test can provide. It may seem like too much effort or expense to run more than one test, but the FDA is strongly advising it. Given the mass scale of testing we will need to perform to truly fight the pandemic, additional testing to make sure our results are as accurate as possible is critical.
Our aim is that when we can combine all these evaluations, we may not see that there is one perfect method, but definitely some methods seem to be performing better than others. This may shorten your list of methods to consider when you choose a serology method.
The data is changing every day, expect that this short list will expand, contract, fluctuate, etc. Stay tuned.
|Test||Sensitivity PPA||PPA n||Specificity NPA||NPA n||PASS FDA 90-95?||Source|
|Abbott Alinity I SARS-CoV-2 IgG||100||88/88||99.63||1066/1070||YES||FDA/IFU|
|Abbott ARCHITECT SARS-CoV-2 IgGAbbott||100||88/88||99.63||1066/1070||YES||FDA/IFU|
|91.8||56/61||99.6||253/254||YES||Pre-print, Mayo Clinic, MN|
|96.9||99.9||1012/1020||YES||Pre-print, University of Washington, Idaho|
|93.8||99.4||YES||Pre-print, University of Washington, St.Louis|
|93.9||77/82||100||757/757||YES||PHE Porton Down evaluation|
|96.8||30/31||99||99/100||YES||Pre-print, University of Kiel, Germany|
|85||17/20||100||100/100||NO||pre-print, Ekelund et al, Växjö Central Hospital, Växjö, Sweden|
|90.5||19/21||100||47/47||YES||JCM, Charlton et al, University of Alberta, Canada|
|92.7||497/536||99.9||993/994||YES||PHE Porton Down evaluation, 4 method comparison >20 days|
|Bio-Rad Platelia SARS-CoV-2 Total Ab||92.2||47/51||99.6||684/687||YES||FDA/IFU|
|95.2||20/21||97.9||48/49||YES||JCM, Charlton et al, University of Alberta, Canada|
|Beckman Coulter Access IgG||96.8||92/95||99.6||1395/1400||YES||FDA/IFU|
|BioMerieux VIDAS SARS-CoV-2 IgG||100||29/29||99.9||988/989||YES||FDA/IFU|
|BioMerieux VIDAS SARS-CoV-2 IgM||100||23/23||99.4||306/308||YES||FDA/IFU|
|Diasorin Liaison SARS-CoV-2 S1/S2 IgG||97.6||40/41||99.3||1082/1090||YES||FDA/IFU|
|94.4||17/18||96.9||68/69||YES||pre-print, Erasmus MC, Rotterdam, Netherlands|
|91.3||116/127||97.0||1339/1380||YES||pre-print, University of Pavia >5 days|
|90.3||28/31||96||96/100||YES||Pre-print, University of Kiel, Germany|
|95||509/536||98.6||980/994||YES||PHE Porton Down evaluation, 4 method comparison >20 days|
|Diazyme DZ-Lite SARS-COV-2 ELISA IgG CLIA||100||29/29||97.4||830/852||YES||FDA/IFU|
|Euroimmun SARS-COV-2 ELISA IgG||90||27/30||100||80/80||YES||FDA/IFU|
|Euroimmun SARS-COV-2 ELISA IgG||90||27/30||100||80/80||YES||FDA study data|
|Euroimmun SARS-COV-2 ELISA IgA||90.5||38/42||88.4||76/86||n/a||pre-print Univ. Chicago, >4 days PCR+|
|Euroimmun SARS-COV-2 ELISA IgG||100||42/42||97.7||84/86||YES||pre-print Univ. Chicago, >4 days PCR+|
|Euroimmun SARS-COV-2 ELISA IgG||93.8||15/16||95.7||22/23||YES||pre-print Institute for Medical Virology, Frankfurt, Germany|
|Euroimmun SARS-COV-2 ELISA IgA||86.7||13/15||80||16/20||n/a||pre-print, Montellier University, France|
|Euroimmun SARS-COV-2 ELISA IgG||86.7||13/15||85||17/20||NO||pre-print, Montellier University, France|
|Euroimmun SARS-COV-2 ELISA IgG||87.3||62/71||84.8||95/112||NO||pre-print, hospitalized patients, University Geneva Hospitals, Switzerland, 11-20 days patients|
|Euroimmun SARS-COV-2 ELISA IgG||80.5||33/41||84.8||95/112||NO||pre-print, outpatient patients, University Geneva Hospitals, Switzerland 11-20 days patients|
|Euroimmun SARS-COV-2 ELISA IgG||96.15||25/26||99.38||160/161||YES||pre-print, Erasmus MC, Rotterdam, Netherlands|
|Euroimmun SARS-COV-2 ELISA IgA||1||26/26||93.79||151/161||n/a||pre-print, Erasmus MC, Rotterdam, Netherlands|
|Euroimmun SARS-COV-2 ELISA||100||61/61||98||249/253||YES||Pre-print, Mayo Clinic, MN|
|Euroimmun SARS-COV-2 ELISA IgA||85.4||94.8||n/a||Pre-print, University of Washington, St.Louis|
|Euroimmun SARS-COV-2 ELISA||87.1||27/31||97||97/100||NO||Pre-print, University of Kiel, Germany|
|Euroimmun SARS-COV-2 IgA/IgG||89.5||17/19||100||50/50||NO||JCM, Charlton et al, University of Alberta, Canada|
|InBios SCoV-2 Detect IgG ELISA||95.45||21/22||98.95||94/95||YES||FDA/IFU|
|InBios SCoV-2 Detect IgG ELISA||96.7||29/30||98.8||79/80||YES||FDA/IFU|
|Luminex xMAP SARS-CoV02 Multi-Antigen IgG Assay||96.3||79/82||99.3||599/603||YES||FDA/IFU|
|Mount Sinai Hospital COVID-19 ELISA Ab||92.5||37/40||100||74/74||YES||FDA/IFU|
|Ortho-Clinical VITROS Anti-SARS-CoV-2 IgG||90.0||36/40||100||407/407||YES||FDA/IFU. Updated.|
|Ortho-Clinical VITROS Anti-SARS-CoV-2 IgG||100||61/61||99.6||253/254||YES||Pre-print, Mayo Clinic, MN|
|Ortho-Clinical VITROS Anti-SARS-CoV-2 IgG||79.7||63/79||99.7||390/391||NO||PHE Porton Down evaluation|
|Ortho-Clinical VITROS Anti-SARS-CoV-2 Total Reagent||100||49/49||100||400/400||YES||FDA/IFU|
|Roche Elecsys Anti-SARS-CoV-2||100||29/29||99.8||5262/5272||YES||FDA/IFU|
|87.7||64/73||100||387/387||NO||PHE Porton Down evaluation|
|91.7||55/60||91.1||72/79||NO||pre-print, Clinique St Luc Bouge, Belgium, Julien Favresse et al >14 days|
|100||20/20||98||98/100||YES||pre-print, Ekelund et al, Växjö Central Hospital, Växjö, Sweden|
|96.8||30/31||99||99/100||YES||Pre-print, University of Kiel, Germany|
|99.5||184/185||99.8||10,432/10,453||YES||Pre-print, Internal Roche Study, >14 days|
|97.1||68/70||100||714/714||YES||Pre-print, Changi, Singapore, > 14 days|
|76.2||16/21||100||50/50||NO||JCM, Charlton et al, University of Alberta, Canada|
|97.2||521/536||99.8||992/994||PHE Porton Down evaluation, 4 method comparison >20 days|
|Siemens Atellica SARS-COV-2 IgG/IgM||100||42/42||99.8||1089/1091||YES||FDA/IFU|
|89.4||76/85||100||499/499||NO||PHE Porton Down Evaluation >14 days|
|98.1||526/536||99.9||993/994||YES||PHE Porton Down evaluation, 4 method comparison >20 days|
|Siemens ADVIA SARS-COV-2 IgG/IgM||100||47/47||99.8||1586/1589||YES||FDA/IFU|
|Siemens Dimension Vista SARS-COV-2 Total Antibody||100||72/72||99.8||1526/1529||YES||FDA/IFU >14 days PCR+|
|Siemens Dimension EXL SARS-COV-2 Total Antibody||100||72/72||99.87||1527/1529||YES||FDA/IFU >14 days PCR+|
|Vibrant COVID-19 Ab IgG/IgM||98.11||52/53||98.6||494/501||YES||FDA/IFU|
|Wadsworth New York SARS-CoV Microsphere IA||88||95/108||98.8||428/433||NO||FDA/IFU|